PMID:
J Microbiol Biotechnol. 2019 Sep 9. Epub 2019 Sep 9. PMID: 31546298
Abstract Title:
Oral Administration ofβ-Glucan andAlleviates Atopic Dermatitis-like Symptoms.
Abstract:
Atopic dermatitis (AD) is a chronic inflammatory skin disease of mainly infants and children. Currently, the development of safe and effective treatments for AD is urgently required. The present study was conducted to investigate the immunomodulatory effects of yeast-extractedβ-1,3/1,6-glucan and/or() LM1004 against AD-like symptoms. To purpose,β-1,3/1,6-glucan and/orLM1004 were orally administered to AD-induced animal models of rat (histamine-induced vasodilation) and mouse (pruritus and contact dermatitis) exhibiting different symptoms of AD. We then investigated the treatment effects on AD-like symptoms, gene expression of immune-related factors, and gut microbiomes. Oral administration ofβ-1,3/1,6-glucan (0.01g/kg initial body weight) and/or 2×10cells/gLM1004 (0.01g/kg initial body weight) to AD-induced animal models showed significantly reduced vasodilation in the rat model, and pruritus, edema, and serum histamine in the mouse models (
Health Time 